Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Modalis Therapeutics Corporation ( (JP:4883) ) has issued an announcement.
Modalis Therapeutics Corporation announced the issuance of 300 new shares as part of a restricted-stock-based remuneration plan. This initiative aims to enhance the company’s long-term value and align employee interests with shareholder value. The impact on the company’s share dilution is minimal, and the plan is designed to incentivize employees by offering them a stake in the company’s future success.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. The company focuses on developing innovative therapies, with a particular emphasis on genetic medicine and therapeutics.
Average Trading Volume: 1,365,124
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.81B
For an in-depth examination of 4883 stock, go to TipRanks’ Overview page.